Drugs · Brain health technique

Anti-Amyloid Monoclonal Antibodies

Evidence grade: Context Dependent

Illustration for Anti-Amyloid Monoclonal Antibodies

FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™). These antibodies enhance immune-mediated clearance of amyloid from the brain, aiming to preserve cognitive function in early-stage disease.

Practice
Drugs
Principle
Treatment
Tactic
Neuroprotective & Disease-modifying Therapies
Evidence grade
Context Dependent
Strength of evidence
Medium
Effort
Medium
Time commitment
High

How to practice Anti-Amyloid Monoclonal Antibodies

Indicated for early Alzheimer’s confirmed by amyloid PET and cognitive testing. Administered via IV infusion every 2–4 weeks in specialized centers. Requires MRI monitoring for ARIA and APOE genotyping. Benefits are disease-modifying but partial; not for late-stage disease or asymptomatic use. Best outcomes occur with early diagnosis and concurrent vascular/metabolic optimization.

The evidence behind Anti-Amyloid Monoclonal Antibodies

Anti-amyloid antibodies are lab-made immune proteins that latch onto clumps of amyloid. The antibodies help your brain's immune cells clear it away and may lower inflammation. Evidence that the antibodies reduce amyloid is strong. The main risk is ARIA (amyloid-related imaging abnormalities): brain swelling or tiny bleeds seen on scans. It's more likely in carriers of the APOE-ε4 gene variant.

Impact on brain health

Large late-stage trials show these drugs slow cognitive decline by roughly 25 to 35% compared with placebo. The trials enrolled people with early Alzheimer's confirmed by a scan, at the mild cognitive impairment or mild dementia stage. Evidence for benefit in how people actually feel and function is modest.

Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science

Pair this with other habits from the same practice.

  • Evidence grade: Context Dependent

    Antihypertensives

    Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

    Low effort · High cost

  • Evidence grade: Context Dependent

    GLP-1 Receptor Agonists

    A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.

  • Evidence grade: Context Dependent

    Lipid-Lowering Drugs

    Therapies that reduce LDL cholesterol and vascular inflammation, including statins (atorvastatin, rosuvastatin, simvastatin), PCSK9 inhibitors (alirocumab, evolocumab), and ezetim…

    Low effort · High cost

See all 20 drugs techniques →

Take control of your brain health

BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.

How BetterBrain worksSee pricing